FDA Approval: Polivy for Relapsed, Refractory Diffuse Large B-Cell Lymphoma – Drug for nerve pain boosts high for opioid abusers.

1806_Graphic-Image_PinteresAabama Defense Lawyer, Board of Pharmacy, Pharmacy Defense Attorney, KLF

FDA Approval: Polivy for Relapsed, Refractory Diffuse Large B-Cell Lymphoma – Drug for nerve pain boosts high for opioid abusers. (866) 348-2889

Officials with the FDA granted accelerated approval to polatuzumab vedotin-piiq (Polivy) in combination with bendamustine plus rituximab (Rituxan) (BR) for the treatment of adults with relapsed or refractory diffuse large B-cell lymphoma (DLBCL) who have received at least 2 prior therapies, according to a press release.

With approximately 25,000 new cases expected to be diagnosed in 2019, DLBCL is the most common form of non-Hodgkin lymphoma. However, the disease can become more difficult to treat upon multiple relapses or no response to treatment, and as many as 40% of patients will relapse.

CLICK HERE FOR CONTINUE READING

This entry was posted in Pharmacist and tagged , , , . Bookmark the permalink.

Comments are closed.